Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Zeta Global Holdings Corp (ZETA) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Zeta Global (ZETA) trades at $33.80, up 0.87% today, showing strong momentum with seven consecutive quarters of earnings beats. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Revenue growth accelerated to $1.3 billion in 2025 with improving margins, while analyst consensus remains strongly positive with 76% buy ratings and a $37.09 price target. Recent expansion into the UK market and AI platform adoption continue to drive investor optimism.

ZETA presents a compelling growth story with accelerating revenue and expanding customer base, though negative net margins and elevated valuation multiples warrant caution. The stock's proximity to 52-week highs combined with strong institutional support suggests continued upside potential, but investors should monitor margin improvement and competitive pressures in the AI marketing technology space.